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Abstract
Preeclampsia is a disease of pregnancy that affects approximately 3-5% of women with
child. It is one of the primary causes of mortality in mothers and babies across the globe.
The exact cause, pathogenesis, or disease progression is unknown. Therefore, there is no
definition of which patients are at risk for developing preeclampsia and what can work as
a preventative measure. In high socioeconomic settings where there is good healthcare,
standard treatment is established to manage the symptoms and decrease the progression
of preeclampsia to eclampsia. However, in more rural, third-world settings of developing
countries, caring for patients with preeclampsia is not a straightforward matter. Due to
decreased access to health care, low economic status, and lack of education, preeclampsia
is often seen yet seldom treated among this population. The discussion below addresses
several possible pathophysiological processes of preeclampsia, as well as potential risk
factors. The standard treatments of care are then discussed, followed by the evaluation of
studies regarding alternative treatments for preeclampsia. The importance of screening
pregnant women in developing nations is included. The discussion is concluded by a
summary of what caring for preeclampsia in a third-world setting might look like for a
missionary nurse.
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A Practical Understanding of Preeclampsia for a Nurse in a Third-World Setting
Disease: this word, simply a summation of letters, is one that makes people shiver
with horror and dread. Disease causes people to evaluate themselves and look deep into
their hearts to what is the meaning and significance of their lives. As Warwick Anderson
sums up all too well, disease brings into focus concerns on the way we live our lives, our
relationships to community, our environment, the cosmos, and challenges us to explain
the purpose of suffering (Anderson, 2000). Disease brings about even more confused
questioning and evaluation when it touches the lives of infants and children. For this
reason, illnesses that affect infants and the young are often given much consideration,
research, and resources in order to give these children a greater chance to live life.
However, as sickness and disease involve the tiny intricacies of creation our human
minds can never fully comprehend, many diseases have no cure, or even a definitive
cause. Preeclampsia is just such a disease. Much research has been poured into searching
for a cause for this disease of pregnancy, so a cure might be discovered. However,
research is no closer to preventing preeclampsia than when it started.
What is Preeclampsia?
Preeclampsia is a pregnancy-specific disease process that impacts approximately
3-5% of all births. It is one of the primary causes of maternal, fetal, and neo-natal
mortality, particularly in low socioeconomic settings and third-world countries (Mol et
al., 2016). Traditionally, it is diagnosed when a pregnant woman presents with symptoms
of hypertension and proteinuria. If preeclampsia continues untreated, patients often
advance to eclampsia, experiencing severe complications. These complications often
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involve seizures, liver rupture, pulmonary edema, stroke, or kidney failure (Mol et al.,
2016). Preeclampsia also affects the growth of the baby, as it affects uterine perfusion.
Due to hypertension involved in preeclampsia, blood flow to the fetus is altered, leading
to fetal growth restriction and preterm birth, either spontaneous or through iatrogenic
delivery. In addition to impacting the fetus during pregnancy, children who are born to
mothers with preeclampsia can be permanently impacted as they have a high risk of
bronchopulmonary dysplasia and cerebral palsy (Mol et al., 2016). These complications
and others are caused by altered blood flow to the fetus during pregnancy and by preterm
birth, as many preterm neonates are small for gestational age.
Diagnostic Criteria
The classic diagnostic criteria for a pregnant woman with preeclampsia were
established by the International Society for the Study of Hypertension (ISSHP) in 2014.
The ISSHP defined preeclampsia as de-novo, or new, hypertension that presents after 20
weeks gestation combined with protein in the urine (>300 mg/day), neurological or
hematological complications, maternal organ dysfunction, renal insufficiency,
uteroplacental dysfunction, liver involvement, or fetal growth restriction (Mol et al.,
2016). As preeclampsia has many different presentations of the disease, the definition has
been changed to no longer require proteinuria in the definition. Therefore, preeclampsia
can now be split into two separate categories: proteinuric and non-proteinuric.
Hypertension is defined as a systolic blood pressure that is higher than 140 mmHg, or a
diastolic blood pressure greater than 90 mmHg. To be diagnosed with hypertension, the
patient must meet these qualifications at two different blood pressure readings that are
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taken at least 4-6 hours apart. The patient should be seated and in an upright position, or
in a left lateral recumbent position (Mol et al., 2016). Whereas hypertension is very
typical of preeclampsia, proteinuria is not always a clear indicator of the disease. Women
with proteinuria tend to have high antenatal blood pressures, deliver at an earlier stage of
gestation, and often need an operative delivery (Mol et al., 2016).
Pathophysiology of Preeclampsia
The exact pathophysiological mechanisms that produce the clinical symptoms of
preeclampsia are unknown. However, there have been numerous conjectures on how the
disease progresses at the tissue level. It is thought the clinical symptoms of the disease
during pregnancy represent later stages of the disease progression. Therefore, the
pathophysiological changes in the body most likely begin taking place long before it is
realized. The pathology of preeclampsia is thought to most likely originate in the placenta
during the development of the uteroplacental circulatory system. One reason for this
thought is that the delivery of the fetus and the placenta at birth is the one and only cure
found for the disease process (Moncrieff, 2018). Therefore, since the disease process is
resolved by the delivery of the baby and the placenta, it most likely starts at the beginning
stages of gestation.
Alteration in Angiogenesis
Under normal circumstances in the body of the mother, the establishment of
uteroplacental circulation involves maternal spiral arteries transforming from smalldiameter, high resistance arteries into low-resistance, high-volume vessels that can fully
perfuse the intervillous space. This transformation begins at approximately 8-10 weeks
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gestation, when cytotrophoblasts enter into the wall of the uterus and take on some of the
characteristics of the cells that make up blood vessels (Moncrieff, 2018).
Cytotrophoblasts do this by aiding in increasing the levels of proteins that make up
endothelial and smooth muscle cells, and slightly decreasing levels of proteins that make
up epithelial cells. This leads to cytotrophoblast formation that looks similar to an
endothelial, or smooth muscle phenotype. This results in the ‘vascular mimicry’ that is
seen in preeclampsia as cytotrophoblasts invade the uterine wall. As they travel through
the stroma of the uterine wall, these cells cross into walls of the maternal spiral arteries
and move up these blood vessels. As the cytotrophoblasts work their way up the spiral
arteries, they replace the endothelial lining and some parts of the smooth muscle layer
(Moncrieff, 2018). The loss of these muscle layers in the maternal spiral arteries changes
the vessels from thin, small-diameter vessels into high-capacity, low-resistance arteries.
Since the cytotrophoblasts remove many neuromuscular and baroreceptor components of
these spiral arteries, the vessels are no longer very responsive to modulators, allowing
these arteries to sustain a low-velocity, but high-volume flow to the intervillous space
(Moncrieff, 2018). In this way, the mother’s body naturally transitions to providing
enough blood flow to the developing fetus.
In preeclampsia it is thought this transformation of the spiral arteries remains
incomplete. In the pathology of preeclampsia, cytotrophoblasts are unable to fully
migrate into the maternal spiral arteries. Therefore, many of the mother’s blood vessels
are incompletely transformed or are not transformed at all (Moncrieff, 2018). In normal
uteroplacental circulatory transformation, the changes to the spiral arteries extend into the
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myometrium of the arteries. In preeclampsia, however, the myometrial portion of many
of the vessels is unaltered. Therefore, mothers with preeclampsia retain arteries with thick
muscular walls and a highly functioning adrenergic nerve supply. These vessels remain
small-diameter, high-resistance arteries that provide a low-volume, high-pressure flow to
the placenta (Moncrieff, 2018). In addition, intact neurological components and
baroreceptors allow the nerves of these vessels to greatly impact the blood flow to the
placenta. This overall incomplete transformation of the maternal spiral arteries causes
decreased perfusion to the placenta and a high blood pressure flow that is subject to
vasoconstriction in response to the mother’s systemic responses. This leads to placental
ischemia and lack of perfusion, and therefore oxidative stress. This is thought to result in
the release of cytokines and anti-angiogenic proteins into the mother’s blood, which
alters vascular growth and permeability (Moncrieff, 2018). In the preeclamptic mother,
the high-pressure blood flow that perfuses the intervillous space leads to
syncytiotrophoblast particles being released into the mother’s blood. These by-products
of placental stress cause the maternal signs of endothelial damage, increased vascular
resistance, and increased coagulation and hemostasis (Moncrieff, 2018).
Alterations in Immune Adaptation
Yet another theory on the pathogenesis and development of preeclampsia is based
on the significant and detailed immune adaptations that take place in the mother’s body
during pregnancy (Alrahmani & Willrich, 2018). The goal of these immune adaptations is
to maintain a competent immune system in the mother in order to fight off disease, while
preventing rejection of the growing fetus. This complex phenomenon is known as
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maternal-placental immune tolerance. The changes that take place in the mother’s body
are multi-faceted. The immune response cytokine profile gradually changes from Thelper 1 to T-helper 2. The activation of T cells in general is suppressed overall, and with
the help of the enzyme indoleamine-2,3-dioxygenase, the production of natural killer
cells is decreased and substituted with the manufacturing of macrophages and
syncytiotrophoblasts. The amount of granulocytes in the mother’s blood stream increases
at the same rate as the levels of acute-phase proteins. In summary, the innate immune
system is enhanced in pregnancy, while components of the adaptive immune system are
suppressed. The complement system is also a critical part of the innate immune system
(Alrahmani & Willrich, 2018). The complement system acts to regulate tissue
homeostasis. There are three separate pathways that play a part in the complementary
system. These pathways are the classical, alternative, and lectin/mannose-binding
pathways. Each pathway is induced by different threats to the body’s homeostasis or
pathogenic agent. The classic pathways are induced by an antigen-antibody immune
complex or a C-reactive protein (CRP). The alternative pathway is always active to some
degree at low levels, as it plays a role in the general health and immune processes of the
body. Finally, the lectin/mannose-binding pathway is activated by mannose-containing
bacteria (Alrahmani & Willrich, 2018). All three pathways converge into a C3 mediated
loop. The activation of the enzyme C3 by C3 convertases leads to the binding and tagging
of foreign cells or bacteria. This is how the complement pathways regulate the innate
immune system.
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One well-accepted theory regarding the pathogenesis of preeclampsia as related to
the immune system is that of immune maladaptation. It is the idea that the normal
immunologic changes a mother’s body goes through during pregnancy are altered by a
factor in the placenta that leads to an increased adaptive immune system and decreased
changes in the innate immune system. This therefore would lead to an increased immune
response against the fetus, which is an allograft that contains paternal antigens. The
innate immune system of the mother would experience only slight alterations, leading to
a heightened immune response during pregnancy. This would cause inflammation, altered
angiogenesis, and increased endothelial activation that are seen in preeclampsia
(Alrahmani & Willrich, 2018). Let it be understood, however, the precise
pathophysiological mechanisms of preeclampsia and their effect of endothelial
dysfunction and hypertension are still unclear and undergoing extensive research.
Risk Factors for Developing Preeclampsia
As there is no definitive cause for preeclampsia, treating, preventing, and
identifying at-risk populations often is a complicated matter. In a study conducted in the
U.S. on clinical risk factors for preeclampsia in the 21st century, two thousand six
hundred thirty-seven women were included in the analysis (Pare et al., 2014). Over the
process of the study, seven hundred ninety-three were excluded for the following reasons:
sponsor request or decision, protocol deviation, participant missed two study visits or
more, participant withdrew consent, incomplete delivery data, spontaneous or induced
termination of pregnancy, or transfer of care. The women involved in the study were
recruited at three different hospitals from three different areas of the country (Pare et al.,
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2014). Out of the women who finished the study, one hundred sixty-five (6.2%) had a
preexisting case of chronic hypertension. The rate of hypertensive disorders that
developed over the progression of pregnancy were as follows: three hundred seventyeight (14.3%) developed gestational hypertension, two hundred thirty-seven (9.0%)
developed preeclampsia, one hundred ninety-four (7.4%) developed severe preeclampsia,
thirty-nine (1.5%) developed a syndrome consisting of hemolysis, elevated liver
enzymes, and low platelet count (HELLP syndrome), and one patient (0.04%) progressed
to eclampsia. The mean gestational delivery age of the patients who did not develop
preeclampsia was 38.8 weeks (standard deviation of 2.0), while for women who did
develop preeclampsia, the mean gestational age at delivery was 37.0 weeks (standard
deviation of 2.7) (Pare et al., 2014). In the discussion of this study, it was found many of
the previously and commonly reported risk factors for preeclampsia proved to be true.
Medical conditions such as chronic hypertension and diabetes have been shown to be
potential risk factors for preeclampsia. Multiple gestation, African American race, use of
assisted reproductive techniques, prior cases of preeclampsia, nulliparity, and obesity
were also confirmed to be independent predictors of preeclampsia and severe
preeclampsia. However, in contrast to previous studies performed, the factor of advanced
maternal age was not associated with an increased risk for preeclampsia. In addition to
this, being overweight or obese was the most prevalent risk factor for both mild and
severe preeclampsia in the patient population involved in the study (Pare et al., 2014).
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Preventative Risk Factors of Preeclampsia
This study particularly highlighted risk factors that should help in affecting and
guiding prevention of preeclampsia in a health care perspective. Until recently,
preeclampsia has been treated from a purely pharmacological standpoint since not much
is known about it. This is partly resultant to clinical prediction rules and scoring having
often been limited to nonmodifiable risk factors such as medical conditions, nulliparity
and race. Therefore, there was not much that could be done to prevent preeclampsia.
However, the above discussed study highlights one modifiable risk factor that represented
the greatest risk factor: obesity. Since it is modifiable, preventive measurements should
be implemented. Given the obesity-attributable risk in the study, great efforts to prevent
preeclampsia should focus on prevention of obesity in women who are pregnant or even
of reproductive age. The percentage of cases of preeclampsia in the study that could be
associated with obesity was 64.9% of all the cases of preeclampsia and severe
preeclampsia (Pare et al., 2014). From a clinical perspective, the results of the study
highlight the importance of discussing weight with women who are of reproductive age
and possibly including a weight reduction component in pre-conceptional counseling for
obese and overweight women. This is due to results suggesting that even a modest
reduction in BMI before conception could drastically decrease the individual’s risk of
preeclampsia (Pare et al., 2014).
Treatment for Preeclampsia
As has been previously mentioned, much of the focus of treating preeclampsia has
been on pharmacologic treatment over the years. Since preeclampsia’s primary trait is
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hypertension, the National High Blood Pressure Educations Program (NHBPEP)
Working Group Report has focused on targeting high blood pressure treatment in
preeclamptic patients. As summarized earlier, mild hypertension is a systolic blood
pressure (SBP) of 140-150 mmHg or diastolic blood pressure (DBP) of 90-109 mmHg.
Severe hypertension is defined as an SBP >160 mmHg or DBP of >110 mmHg (Berzan,
Doyle, & Brown, 2014).
Standard Treatments of Preeclampsia
Guidelines for treatment according to the American College of Obstetricians and
Gynecologists (ACOG) do not recommend antihypertensive medication for mild
preeclampsia (SBP < 160 mmHg or DBP <110 mmHg). However, antihypertensive
therapy is recommended for women with preeclampsia who have a sustained SBP of
>160 mmHg or DBP of >110 mmHg (Berzan et al., 2014). Although this disease is one
of the most common complications of pregnancy all over the world, there are a limited
number of medications that are used regularly as standards of treatment.
Methyldopa and Labetalol. First-line agents for hypertension in preeclamptic
patients include methyldopa and labetalol. Methyldopa is the drug of choice for
hypertension in pregnant women, as its safety and efficacy have been shown through
many studies. There are some concerns with side effects of depression, hepatic
disturbances, and hemolytic anemia. It also may not lower blood pressures adequately or
fast enough for some preeclamptic patients; therefore, methyldopa should not be used in
emergent situations (Berzan et al., 2014). Labetalol is also a first line therapy. Its safety is
similar to the above-mentioned medication, but labetalol may often be more efficacious

A PRACTICAL UNDERSTANDING OF PREECLAMPSIA

14

than methyldopa. However, it may be associated with possible fetal growth restriction,
and when given in large doses, neonatal hypoglycemia may be seen. Labetalol then is not
the drug of choice over methyldopa due to the side effects (Berzan et al., 2014). Secondline agents for hypertension in preeclamptic patients include nifedipine, verapamil, and
clonidine. For emergency treatment in preeclampsia, intravenous (IV) hydralazine,
labetalol, and oral nifedipine may be used (Berzan et al., 2014).
Magnesium Sulphate. Magnesium sulphate also plays a very crucial role in the
management of preeclampsia and eclampsia. For more than a century, magnesium
sulphate (MgSO4) has been the anticonvulsant of choice to prevent and control eclamptic
fits. Historically, the total dose of magnesium sulfate used in the treatment of
preeclampsia and eclampsia would be gradually increased from 2g/24 hours to as high as
54 g/24 hours with the belief the increase in titration would increase the clinical efficacy
(Okusanya et al., 2015). All studies have shown convulsions are controlled well with
magnesium sulphate, despite the considerable alterations in the regimen, route of
administration, and total dosage used (Okusanya et al., 2015).
The goal in the administration of magnesium sulphate is to achieve physiological
magnesium (Mg2+) homeostasis in the patient. A type of cation, Mg2+ is found all
throughout the body. It works in the activation processes of many enzymes, including
those of energy metabolism. It is critical cation in the production of ATP, therefore
playing a crucial part in the neurological stability of a patient. Women who are pregnant
generally maintain normal levels of Mg2+, with only minor fluctuations over the forty
weeks of gestation. In preeclampsia, however, pregnancy often continues with normal
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Mg2+ levels until generally the 32nd and 33rd weeks of gestation. This cation’s levels
decline at this stage until delivery, with hypomagnesemia at delivery seen in
preeclampsia (Chiarello et al., 2018).
Magnesium sulphate is an inorganic salt that is administered for these patients.
This salt contains Mg2+, oxygen, and Sulphur. Free Mg2+ concentration in maternal
blood is 0.75 mmol/L and 0.83 mmol/L in fetal blood in normal pregnancies. However, in
preeclamptic pregnancies, the value in maternal blood decreases to 0.66 mmol/L and
increases to 1.01 mmol/L in fetal blood (Chiarello et al., 2018). The exact impact of the
increased of Mg2+ levels in fetal blood is unknown at the time, as there is not a clear
explanation for the accumulation of Mg2+. It is universally acknowledged the beneficial
effects of Mg2+ administration are unparalleled, as they mitigate the potential and
associated complications of preeclampsia. However, there is not a clear understanding as
to the potential mechanisms of action of the cation. There are many suggestions as to how
magnesium sulphate alters the fetoplacental vascular function. These include the
magnesium sulphate impacting altered function of Mg2+ transporters, membrane
receptors, inadequate generation of nitric oxide (NO), and an inflammatory and oxidative
state (Chiarello et al., 2018). Parenteral administration of Mg2+ salts works primarily for
the patient with severe preeclampsia to guard prophylactically against eclampsia and
seizures. Although the specific mechanism of Mg2+ is not understood in preeclampsia,
studies show that lower Mg2+ levels are seen in the red blood cell membranes of patients
with preeclampsia in contrast to women with normal pregnancies (Chiarello et al.,
2018).This consistent trend in altered Mg2+ levels in both mother and baby is considered
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to be a predisposing factor in the pathogenesis and development of preeclampsia. Clinical
practice dictates that maintaining a maternal plasma Mg2+ level higher than the normal
range of 0.75-1.0 mmol/L is required to reduce the chance of advancing from
preeclampsia to eclampsia (Chiarello et al., 2018). In addition to this, overall levels of
Mg2+, calcium, creatinine, and proteins, as well as maternal bodyweight, are crucial to
monitor and keep at safe levels in order to achieve a safe and effective delivery (Chiarello
et al., 2018).
In planning care for a pregnant mother, antihypertensive medication and
magnesium sulphate are the standards of care. However, these standards of care are those
that have been determined to work in first world countries in the presence of primary
health care providers. In many areas of the world where there are no primary health
providers, there are great challenges in the prediction, prevention, and management of
preeclampsia (Osungbade & Ige, 2011). The cost and accessibility of such medications as
those which are generally prescribed for treatment of preeclampsia make treatment and
management of the disease very difficult. Treatment in these countries consists of the
following: prenatal care, a timely diagnosis, proper management, and a timely delivery.
The impact of preeclampsia is felt significantly in low income and third world areas since
medical interventions are often ineffective due to the late identification and treatment of
cases of preeclampsia (Osungbade & Ige, 2011).
Screening for Preeclampsia
Prevention of this disease process requires availability of predictive measures for
those at a high risk for developing the disorder. Although countless clinical and
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biochemical tests have been devised for those at risk, most remain quite unrealistic for
common use in developing countries. At the current time, there is no single reliable and
cost-effective screening test for preeclampsia that can be recommended for use in
developing countries (Osungbade & Ige, 2011).
Screening in a Third-World Country
The primary way to efficiently and accurately screen pregnant women for
preeclampsia is the establishment of easily accessible, functional health care systems. In
the majority of developing countries, particularly in areas like Africa and Southern Asia,
there are three levels of delay that result in limited health care access (Osungbade & Ige,
2011). The first is delay in the decision to seek care. This delayed response at the patient
level is often a result of insufficient information on signs and symptoms of the disease
process, as well as inadequate information on where and when to seek help from a
facility. Poverty, corrupt power, and the rising cost of health care lead to often fatal
delays in care seeking (Osungbade & Ige, 2011). The second level is delay in reaching
the health care facility. Lack of access to quality care is often one of the main obstacles to
reducing maternal and neonatal mortality in low income countries. This is often in part
due to the placement of the health care facilities in relation to the location of villages,
distance, and lack of transport to the areas where the health care providers are located.
For example, in Nigeria, up to 50% of rural women live over 5 kilometers from the
nearest hospital. Most of these women have no way of reaching the hospital except by
walking – even when they are in labor. Therefore, most of the pregnant population of
these villages do not make it to the hospital during delivery. For a woman with
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preeclampsia, this lack of treatment could progress to eclampsia, leading to death for both
the mother and baby. This could all take place without the nearest health care facility
knowing anything about the mother and her baby (Osungbade & Ige, 2011). Finally, the
third level of delay is delay in health service provision. In many health facilities in the
third world setting, health care insurance is in the teething stage, making it impossible for
both the poor and the insured to obtain care during emergent situations. Identified barriers
include the attitudes of many of the health service providers as well as the perceived poor
quality of care. These barriers are increased by the lack of trained personnel and the
extreme lack of equipment and supplies. In many cases of preeclampsia in a third world
hospital, studies have shown magnesium sulphate wasn’t routinely administered if it was
available. Another consideration is that the use of magnesium sulphate is often limited
solely to teaching hospitals. The overall lack of availability of the drug and appropriate
health personnel as well as equipment to administer it frequently raises obstacles for
treating preeclamptic women (Osungbade & Ige, 2011).
Using CLIP in a Rural Setting. Globally, hypertensive diseases of pregnancy,
two of the top ones being preeclampsia and eclampsia, are the primary causes of maternal
and neonatal mortality. Therefore, managing preeclampsia and eclampsia in less modern
and first world settings is a priority when evaluating world-wide health initiatives for
mothers and babies around the world (Khowaja et al., 2015). Hypertensive disorders of
pregnancy (HDP), which include pre-eclampsia and eclampsia, complicate over 10
million pregnancies worldwide each year. This results in 76,000 maternal and 500,000
neonatal deaths. The large majority of these deaths (>99%) take place in low- and
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middle-income countries (LMICs), particularly in South Asia and in Sub-Saharan Africa
(Khowaja et al., 2015). The Community Level Interventions for Preeclampsia (CLIP)
trial evaluates a package of care that could be applied at a community level in addition to
being implemented through hospitals and primary health care centers. This package
directly seeks to address and intervene against the three levels of delay mentioned above
(Osungbade & Ige, 2011). If applied appropriately, maternal and perinatal complications
and potential deaths could be reduced drastically in village communities and the third
world setting. As discussed above, management of preeclampsia mainly focuses on
interventions in a primary health facility. These include antihypertensive therapies,
anticonvulsant therapies, and timed deliveries. However, thousands of women in LMICs
are unable to reach facilities that monitor and provide treatment during delivery for those
with preeclampsia. These women in hard-to-reach areas suffer disability and often lose
their lives due to a lack of resources for screening and identification of HDP as well as
triage and transport availability. In a first world country, these clinical processes are at
the reach of almost every woman, allowing a usually safe and monitored delivery
(Khowaja et al., 2015).
How CLIP Works. The goal of the CLIP trial is introducing evidence-based
interventions at community levels through the availability and presence of primary health
care providers. Specifically, the CLIP intervention involves three levels:
I.
II.
III.

Community engagement
Provision of HDP-oriented antenatal care through household visits
Use of the CLIP package for women with a CLIP ‘trigger’
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(Khowaja et al., 2015)
The community engagement level seeks to include all women, particularly those
who are currently pregnant or could become pregnant. It also includes the decision
makers of the households (husbands, father-in-laws, or brothers) and community leaders.
Community engagement involves teaching these groups about preeclampsia, its origins,
signs, symptoms, and potential consequences. It seeks to inform the community about
potential cost for transport and treatment and what that would look like (Khowaja et al.,
2015). The second step, provision of HDP-oriented antenatal care, is done through
household visits to pregnant women. Community healthcare providers (cHCPs) would
travel from home to home with the proper equipment, screening women for potential risk
factors or symptoms of preeclampsia or other HDPs. Since the women and families will
have been previously informed as to what signs and symptoms to look for, in addition to
the potential complications that could arise if left untreated, this step is expected to be
received with cooperation and understanding since community involvement would
already be achieved (Khowaja et al., 2015). Finally, the third step aims to provide a CLIP
package for women who had a CLIP ‘trigger.’ This CLIP package will include oral
antihypertensive therapy or intramuscular magnesium sulphate. Administration of this
package will be accompanied by appropriate education as to the use of these medications.
Appropriate referrals to a comprehensive emergency obstetric care facility will also be
provided, in addition to what transport to the facility would require (Khowaja et al.,
2015). The cHCPs would regularly assess and check up on these women approximately
every 4 weeks at minimum. These visits could be done either in the home, or at a primary
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health care facility, if there is one close by. The cHCPs are trained specifically to screen
the women for symptoms, using culture and country specific pictograms. They also take
the woman’s blood pressure each visit, noting trends or signs of hypertension. The
cHCPs also check urine for protein at the first visit using a dipstick, and then on
following visits if the patient’s systolic blood pressure is over 140 mmHg. This screening
process allows for consistent care and early diagnosis of preeclampsia. Women with
preeclampsia can then be referred to facilities with specific care or given CLIP packets to
take during pregnancy (Khowaja et al., 2015).
Alternative Treatments for Preeclampsia to Use in Third-World Setting
In addition to introducing CLIP interventions in rural and third world settings to
proactively screen and manage patients with preeclampsia, there has been a significant
amount of research performed on alternative therapies and treatments, other than that of
antihypertensive medications and magnesium sulphate (Atallah et al., 2017).
Preventing Preeclampsia with Aspirin
Aspirin is currently the most widely prescribed medication for the prevention of
cardiovascular diseases and complications. However, aspirin may also be indicated for
usage during pregnancy for women who have preeclampsia. Large meta-analyses have
reviewed individual patient data as well as anonymous surveys, demonstrating aspirin is
often very effective in preventing preeclampsia in those patients who are at a high risk for
developing the disease (Atallah et al., 2017). Aspirin has been shown to be particularly
helpful in preventing preeclampsia among those patients who have a history of
preeclampsia. Guidelines regarding the use of aspirin for preeclampsia vary greatly from
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country to country. Types of screening, target population, and the prescribed dosage of
aspirin in preventing preeclampsia are still matters of heated debate (Atallah et al., 2017).
Pathophysiology. To understand the use of aspirin for the treatment of
preeclampsia, the pathophysiology of the disease must be reviewed. In this disease, the
platelet TXA2 increases significantly, while prostacyclin levels drop sharply due to
changes in the mother’s body during pregnancy. Around the 13th week of gestation in
women who are at a high risk for preeclampsia, this imbalance of platelet TXA2 and
prostacyclin is visible. TXA2/PGI2 imbalance can be reversed within 2 weeks of
treatment with a low dose aspirin regimen (Atallah et al., 2017). Aspirin acts by
inhibiting TXA2 secretion, and thus platelet aggregation. However, aspirin doesn’t alter
the secretion of endothelial prostacyclin, correcting the increase of TXA2 and decrease of
PG12. This correction favors maternal systemic vasodilation, resulting in decreased
hypertension and increased blood flow to the uterus and therefore the fetus. More recent
understanding of the impact of angiogenic factors on placental hemodynamics in women
with preeclampsia has led to the study of the impact of aspirin on the secretion of these
factors in the placenta (Atallah et al., 2017). In situations of decreased blood flow, and
therefore hypoxic conditions for the fetus, aspirin inhibits the production of sFlt-1 in
human trophoblasts. This produces proangiogenic results. The factor sFlt-1 is the
common type of vascular endothelial growth factor (VEGF) seen in pregnancy. When it
binds to circulating placental growth factor and other types of VEGFs, it behaves as a
concentrated anti-angiogenic factor. Patients with preeclampsia or who have a history of
preeclampsia have high levels of sFlt-1 in their plasma. Therefore, it is thought that sFlt-1
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is responsible for the angiogenic imbalance seen in the pathophysiology of preeclamptic
patients (Atallah et al., 2017). Since aspirin binds to this factor, angiogenic growth is
promoted, increasing blood flow to the developing fetus and decreasing hypertension in
the mother.
Controversy with the Use of Aspirin. Although numerous and continual studies
have been performed on the potential use of aspirin in preeclamptic mothers, the debate
continues. Even though aspirin does decrease some of the anti-angiogenic results of the
factors in the patient with preeclampsia, aspirin also crosses the placental barrier and
alters TXA2/PGI2 balance and platelet aggregation of the fetus (Atallah et al., 2017).
After it perfuses into the placental cotyledon, aspirin transfers over into the fetalplacental circulation during the first 5 minutes. Laboratory tests performed on blood from
the umbilical cord of pregnant women who are taking low-dose aspirin reveal a sharp
drop in platelet TXA2. Although this acts to decrease hypertension in mothers, there have
been sporadic cases reported of intracranial hemorrhage in premature infants and lowweight fetuses, in addition to early closure of the arterial canal (Atallah et al., 2017).
Therefore, it is presumed that aspirin treatment may lead to a decrease in fetal platelet
aggregation, resulting in an increased chance of utero cerebral hemorrhage. Low dose
aspirin administration doesn’t seem to introduce a teratogenic risk in the first trimester,
but it has been advised aspirin treatment should be discontinued around 36 weeks of
gestation to decrease risks of hemorrhage in mothers and babies (Atallah et al., 2017).
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Preventing Preeclampsia with Calcium Supplements
Pathophysiology. Yet another possible alternative treatment for preeclampsia that
has been investigated is calcium. Preeclampsia is often characterized by inflammation
cascades as well as endothelial activation (DeSousa et al., 2016). This results in the
multi-organ disease that we see in pregnancy. A placental factor that consists of deported
trophoblastic debris is increased in the blood of mothers with preeclampsia. Deported
trophoblastic debris is seen in the blood of mothers in all pregnancies, but increased
levels in preeclamptic mothers is suggested to be from the nature of increased cell death
in the syncytiotrophoblast. In normal pregnancies, the death of syncytiotrophoblasts are
more apoptosis-like, while in preeclampsia, cell death is more necrotic (DeSousa et al.,
2016). Other studies point to placental factors that are related to the process of
angiogenesis, such as sFlt-1, PIGF, and sEndoglin, are involved in the pathogenesis of
preeclampsia. Studies show that levels Flt-1 in the maternal blood flow are directly
proportional to the amount of trophoblastic debris. This trophoblastic debris from a
placenta that is preeclamptic has been treated with preeclamptic sera that is dangerous
and toxic. When this trophoblastic debris is phagocytosed, it leads to endothelial cell
activation and increased levels of inflammatory cytokines (DeSousa et al., 2016). Both
processes are seen in those with preeclampsia.
The alternative treatment to prevent or reduce the risk of preeclampsia is to
provide an antenatal treatment of calcium supplementation. There is currently limited
evidence of low-dose calcium supplementation reducing preeclampsia, requiring larger
and higher quality trials to be performed before a definitive result is can be determined
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(DeSousa et al., 2016). Calcium has been shown in these limited studies to decrease the
activation of endothelial cells in the in vitro setting when the activation of these cells was
caused by necrotic trophoblastic debris, preeclamptic sera, and interleukin (IL)-6. These
factors all are seen in increased levels in preeclamptic patients, leading to increased
activation of endothelial cells. Studies have been specifically targeted at whether the
addition of a calcium supplement at clinically acceptable doses would prevent or decrease
the activation of endothelial cells that were induced by toxic levels of trophoblastic debris
(DeSousa et al., 2016).
Results of Studies. Results from a study which took blood samples from both
preeclamptic women and normotensive pregnant women of the same gestation times
were compiled, studying culture inserts into placental explant cells. The resulting
endothelial cell activation was then closely monitored, after being treated by debris from
trophoblasts. Results showed calcium supplementation decreased or prevented the
activation of endothelial cells by the trophoblastic debris in the placenta from
preeclamptic patients (DeSousa et al., 2016). When the trophoblastic debris from cells
from a preeclamptic placenta were introduced, the expression of ICAM-1 by the cells was
increased as well as the number of monocytes that adhered to the endothelial cells. This
resulted in increased inflammation. However, when calcium was introduced to the
endothelial cells, at the same time as the trophoblastic debris of preeclamptic cells, the
increase in ICAM-1 and monocyte adhesion was reversed (DeSousa et al., 2016).
Calcium supplementation also prevented activation of endothelial cells that was caused
by increased levels of IL-1. These increased levels of IL-1 increased levels of cell-surface
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endothelial ICAM-1. However, at the introduction of supplemental calcium treatment,
this reactive chain was reversed. Therefore, in this vitro study, as in many others, it can
be seen calcium supplements can decrease the activation process of endothelial cells in
the presence of trophoblastic debris from the placenta of preeclamptic patients, as well as
normal placenta that were treated with preeclamptic sera (DeSousa et al., 2016). This
suggests the mechanism by which calcium acts in reducing the risk of a patient
developing the disease of preeclampsia during pregnancy.
Meta-analysis of many studies looking into calcium supplementation as a
potential treatment for preeclampsia show calcium treatment decreases the risk of
preeclampsia by about fifty percent (DeSousa et al., 2016). This is especially true in the
case of women with previous low calcium intake levels. Calcium appears to exert its
mechanism of action, at least in part, by decreasing endothelial action that is caused by
the toxic trophoblastic debris from preeclamptic placenta. In this way, it seems to reverse
one of the direct pathways that leads to the development of increased blood pressure and
inflammation seen in preeclamptic patients. Anti-inflammatory effects appear to be the
result of calcium supplementation (DeSousa et al., 2016). Although the direct cause and
pathogenesis of preeclampsia is unknown, calcium supplementation appears to decrease
the risk or at least the exacerbation of some of the pathways that lead into preeclamptic
conditions.
Conclusion
For a third-world focused nurse, standard treatments and standards of care such as
magnesium sulphate may not always be readily available. However, for women who have
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a history of preeclampsia in past pregnancies or who have pre-gestational hypertension,
supplemental calcium or an increase in high calcium foods may potentially decrease
chances of developing the disease of preeclampsia. If not completely preventing the
disease, calcium may decrease the intensity of the disease as it would decrease some of
the inflammatory pathways. The use of aspirin could also be potentially considered as an
alternative treatment for preeclampsia.
The current interventions that have been studied and established to have the most
clinical significance in diagnosing, preventing, and treating women with preeclampsia or
eclampsia are diagnostics, transferring to a hospital, magnesium sulfate use, and cesarean
section/labor induction (Goldenberg et al., 2014). Typically, diagnosis of preeclampsia
using blood pressure screenings for high risk or hypertensive patients and screening for
proteinuria have proved to be most helpful in determining which patients need further
care as relates to preeclampsia. Either these patients can be transported to a hospital, or
proper medical care can be brought into their area of residence to provide a timely and
safe delivery through cesarean section or through induction of labor. Since the only
determined cure for preeclampsia is the delivery of the baby, thereby ending this disease
through the ending of the pregnancy, mothers with severe preeclampsia often need an
induction of labor to ensure safety for both the mother and baby. However, this early
delivery often leads to slightly preterm infants. This may necessitate the baby spending
some time in the Neonatal ICU, requiring the mother and/or the baby to be sent to a
nearby hospital. For preeclamptic mothers who can wait until their full gestation time is
finished to deliver, magnesium sulfate can be brought in to be administered during the
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delivery process. Preeclamptic mothers can also be taken to a hospital to have this
treatment administered to delay the progression of preeclampsia to eclampsia, reducing
both maternal and fetal mortality (Goldenberg et al., 2014). The highest priority, then, for
the nurse in a third world culture providing treatment for pregnant mothers is to provide
screening for this patient population. If proper screening is performed on all pregnant
mothers, especially those at a high risk for preeclampsia that have a history of
preeclampsia or who are obese, this will allow for early diagnosis and appropriate
planning of treatment. Currently, there is not enough research completed on use of aspirin
in prevention of preeclampsia to suggest that for standard of care. Although it cannot be
decisively concluded whether calcium supplementation prevents preeclampsia, providing
healthy nutrition for pregnant mothers, including calcium supplementation, is a standard
of nursing care for this patient population. These suggestions may lead a nurse in a third
world setting to better prepare for treatment of preeclampsia.
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